tradingkey.logo

CareDx Inc

CDNA
查看詳細走勢圖
19.450USD
+0.260+1.35%
收盤 12/19, 16:00美東報價延遲15分鐘
999.87M總市值
14.42本益比TTM

CareDx Inc

19.450
+0.260+1.35%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.35%

5天

-5.40%

1月

+21.71%

6月

+2.21%

今年開始到現在

-9.15%

1年

-5.35%

查看詳細走勢圖

TradingKey CareDx Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

CareDx Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名6/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價23.00。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

CareDx Inc評分

相關信息

行業排名
6 / 404
全市場排名
59 / 4582
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 9 分析師
買入
評級
23.000
目標均價
+21.69%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

CareDx Inc亮點

亮點風險
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
業績轉盈
公司業績轉盈,最新年度盈利美元
估值高估
公司最新PE估值14.42,處於3年歷史高位
機構加倉
最新機構持股52.64M股,環比增加0.08%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉14.98K股

CareDx Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

CareDx Inc簡介

CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
公司代碼CDNA
公司CareDx Inc
CEOHanna (John W)
網址https://www.caredx.com/

常見問題

CareDx Inc(CDNA)的當前股價是多少?

CareDx Inc(CDNA)的當前股價是 19.450。

CareDx Inc 的股票代碼是什麼?

CareDx Inc的股票代碼是CDNA。

CareDx Inc股票的52週最高點是多少?

CareDx Inc股票的52週最高點是25.950。

CareDx Inc股票的52週最低點是多少?

CareDx Inc股票的52週最低點是10.960。

CareDx Inc的市值是多少?

CareDx Inc的市值是999.87M。

CareDx Inc的淨利潤是多少?

CareDx Inc的淨利潤為52.55M。

現在CareDx Inc(CDNA)的股票是買入、持有還是賣出?

根據分析師評級,CareDx Inc(CDNA)的總體評級為買入,目標價格為23.000。

CareDx Inc(CDNA)股票的每股收益(EPS TTM)是多少

CareDx Inc(CDNA)股票的每股收益(EPS TTM)是1.349。
KeyAI